Efficacy and biomarker analysis of nivolumab plus gemcitabine and cisplatin in patients with unresectable or metastatic biliary tract cancers: results from a phase II study

BACKGROUND: The prognosis of patients with unresectable or metastatic biliary tract cancer (BTC) is unacceptably low. This study aimed to determine the efficacy, safety and predictive biomarkers of the immune checkpoint inhibitor nivolumab in combination with chemotherapy in advanced BTCs. METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales: Feng, Kaichao, Liu, Yang, Zhao, Yongtian, Yang, Qingming, Dong, Liang, Liu, Jiejie, Li, Xiang, Zhao, Zhikun, Mei, Qian, Han, Weidong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7269541/
https://www.ncbi.nlm.nih.gov/pubmed/32487569
http://dx.doi.org/10.1136/jitc-2019-000367

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7269541/
https://www.ncbi.nlm.nih.gov/pubmed/32487569
http://dx.doi.org/10.1136/jitc-2019-000367

Ejemplares similares